Plasma Kallikrein

A peptidohydrolytic enzyme that is formed from PREKALLIKREIN by FACTOR XIIA. It activates FACTOR XII; FACTOR VII; and PLASMINOGEN. It is selective for both ARGININE and to a lesser extent LYSINE bonds. EC 3.4.21.34.

Also Known As:

Networked: 344 relevant articles (14 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Feener, Edward P: 17 articles (01/2022 - 02/2009)
2.	Colman, Robert W: 9 articles (01/2018 - 09/2004)
3.	Bernstein, Jonathan A: 8 articles (01/2021 - 01/2010)
4.	Clermont, Allen C: 7 articles (01/2022 - 02/2009)
5.	Schmaier, Alvin H: 7 articles (01/2018 - 12/2002)
6.	Cornpropst, Melanie: 6 articles (01/2022 - 01/2016)
7.	Murugesan, Nivetha: 6 articles (01/2022 - 09/2015)
8.	Riedl, Marc A: 6 articles (11/2021 - 01/2017)
9.	Li, H Henry: 6 articles (01/2021 - 08/2010)
10.	Wu, Yi: 6 articles (10/2019 - 11/2012)

Related Diseases

1.	Hereditary Angioedemas 11/01/2023 - "An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial." 01/01/2022 - "Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade." 01/01/2020 - "Inhibitors of plasma kallikrein have recently been approved for prophylaxis of hereditary angioedema and are under investigation for use in other indications. " 09/17/2019 - "Inhibitors of plasma kallikrein have recently been approved for prophylaxis of hereditary angioedema and are under investigation for use in other indications. " 01/01/2018 - "Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema."
2.	Angioedema 12/01/2019 - "Further studies are needed to test its efficacy also in other types of angioedema for which a central role of plasma kallikrein is envisaged." 11/01/2018 - "Stimulated plasma kallikrein activity (mean relative fluorescence units/min ± SD) was significantly increased in both HAE-nl-C1INH (1804 ± 600) and INHA (1579 ± 371) subjects compared to non-swelling controls (171 ± 46) and histaminergic angioedema (133 ± 30) subjects. " 09/01/2018 - "Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1-INH-HAE) by reducing the frequency of angioedema attacks. " 12/01/2003 - "Plasma kallikrein is believed to be an important mediator of angioedema in patients with genetic deficiency of C1 esterase inhibitor (HAE patients). " 01/01/2020 - "The understanding of some mechanisms in angioedema has been improved, compatible to the dominant-negative for some C1 inhibitor variants; furthermore, the increased activation of truncated F12 mutants by plasma kallikrein; and the diminished binding of angiopoietin-1 to its receptor. "
3.	Macular Edema 03/01/2020 - "It discusses early clinical studies of plasma kallikrein pathway modulation for DME, which have been associated with some improvement in visual acuity but with limited improvement in macular edema. " 12/01/2021 - "Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema." 12/01/2021 - "We show that the model accurately describes circulating levels of THR-149, a plasma kallikrein inhibitor in development for the treatment of diabetic macular edema. " 10/04/2021 - "To investigate the effect of plasma kallikrein (PKal)-inhibition by THR-149 on preventing key pathologies associated with diabetic macular edema (DME) in a rat model. " 03/01/2020 - "Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. "
4.	Stroke (Strokes) 05/01/2015 - "Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation." 01/01/2022 - "Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats." 01/01/2014 - "Selective and specific kinin receptor antagonists and inhibitors of plasma kallikrein and coagulation factor XII have been developed, and have already shown therapeutic efficacy in animal models of stroke and TBI. " 01/01/2017 - "Although plasma kallikrein (PKal) has been implicated in contributing to both hematoma expansion and thrombosis in stroke, its role in the complications associated with the therapeutic use of tPA in stroke is not yet available. " 09/01/2007 - "The plasma kallikrein-kinin system (PKKS) has been implicated in cardiovascular disease, but activation of the PKKS has not been directly probed in individuals at risk of coronary heart disease (CHD) or stroke. "
5.	Hemorrhage 02/01/2007 - "The goal of this study was to explore the relationship among endogenous plasma kallikrein inhibition (KI), perioperative bleeding, and adverse outcomes in cardiac surgery. " 12/01/2010 - "Plasma kallikrein (PK) is activated during hemorrhage and has been implicated in cerebral vascular permeability and edema. " 02/15/2015 - "The plasma kallikrein stimulates retinal vascular permeability and intraocular hemorrhage. " 02/07/2013 - "Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein." 01/01/2022 - "Plasma kallikrein (PKa) has been implicated in contributing to hemorrhage following thrombolytic therapy; however, its role in spontaneous intracerebral hemorrhage is currently not available. "

Related Drugs and Biologics

1.	Kinins
2.	Peptide Hydrolases (Proteases)
3.	Complement System Proteins (Complement)
4.	Bradykinin
5.	Factor XII (Hageman Factor)
6.	Monoclonal Antibodies
7.	Bradykinin B2 Receptor
8.	Glycoproteins (Glycoprotein)
9.	Fibrinolysin
10.	Retinaldehyde (Retinal)

Related Therapies and Procedures

1.	Intravitreal Injections
2.	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
3.	Therapeutics
4.	Hip Replacement Arthroplasty (Total Hip Replacement)
5.	Thrombolytic Therapy